98-LB: Efficacy and Clinical Considerations of Flash Glucose Monitoring among Canadian Adults with Diabetes
Bibliographic record
Abstract
The FreeStyle Libre flash glucose monitoring (FGM) system was introduced in Canada in 2017. FGM incorporates aspects of conventional blood glucose testing and continuous glucose monitoring (CGM). The FreeStyle Libre utilizes a sensor placed on the upper arm to test interstitial glucose levels every fifteen minutes and may be used to obtain a ‘flash’ (real-time) reading. The FreeStyle Libre system is less costly than CGM and may help overcome common barriers to conventional glucose testing, including pain, needle aversion, and inconvenience, but at present there is no public coverage for the product available in Canada. In this study, we investigated the continuation rate of FGM use in patients provided complimentary FreeStyle Libre starter packs, consisting of one reader and two 14-day sensors, and the impact of continued use on glycemic control. More than half (21/40) continued to use the system beyond the trial period. The mean A1C of patients who continued using FGM decreased by 1.14% at three months, compared to an increase of 0.17% in those who did not (p=0.038). Despite small sample size, there was also a trend of decreased basal and bolus insulin requirements in patients continuing use. These results show benefit and support the implementation of public coverage because greater adherence of self-monitoring of blood glucose results in improved glycemic control which ultimately reduces the risk of long-term diabetes associated complications and healthcare costs. Disclosure A. Jazdarehee: None. J.E. Kapeluto: None. M. Pawlowska: None. J. MacKenzie-Feder: None. B. Schroeder: Advisory Panel; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., LifeScan Canada, Natesto, Sanofi-Aventis. Speaker’s Bureau; Self; AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk Inc. A. White: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk Inc., Sanofi. Speaker’s Bureau; Self; Merck & Co., Inc. Other Relationship; Self; Diabetes Canada.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.009 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.002 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".